局部晚期头颈鳞癌每周6次对比5次放化疗的全国队列研究
基于瑞典头颈癌登记的前瞻性数据,比较局部晚期头颈鳞癌患者在接受以同步放化疗为主的治疗时,每周6次与每周5次放疗的疗效。6次/周组405例(其中320例接受放化疗),5次/周组535例(其中352例接受放化疗),两组基线特征相似。5年总生存率分别为67%与66%(HR 0.93,95%CI 0.73-1.19),5年局部区域控制率6次/周组显著更优(84% vs 78%,HR 0.69,95%CI 0.49-0.97),但未带来总生存获益。
要点
- 6次/周中度加速放疗可显著改善局部区域控制,5年LRC 84% vs 78%(HR 0.69)。
- 总生存无显著差异,5年OS 67% vs 66%(HR 0.93,95%CI 0.73-1.19)。
- 亚组分析结果一致,p16阴性头颈鳞癌的绝对获益更大。
核心结论
- 在以同步放化疗为主的局部晚期头颈鳞癌患者中,每周6次中度加速放疗较每周5次改善了局部区域控制,但未带来总生存获益。
研究设计与样本
- 瑞典全国前瞻性头颈癌登记资料的队列研究,纳入2017年起六个医疗区域内符合条件的≤70岁局部晚期头颈鳞癌放疗患者,三个区域采用5次/周、三个区域采用6次/周方案。
主要发现
- 6次/周组405例(320例放化疗)与5次/周组535例(352例放化疗)基线特征相似。
- 中位总治疗时间6次/周组为40天(IQR 38-43),5次/周组为46天(IQR 46-49)。
- 5年OS为67% vs 66%(HR 0.93,95%CI 0.73-1.19),5年LRC为84% vs 78%(HR 0.69,95%CI 0.49-0.97)。
- 亚组分析结果保持一致,p16阴性头颈鳞癌的绝对获益更大。
关键数值与推荐
- 5年局部区域控制:6次/周组84%,5次/周组78%,HR 0.69(95%CI 0.49-0.97)。
- 5年总生存:6次/周组67%,5次/周组66%,HR 0.93(95%CI 0.73-1.19)。
临床怎么用
- 对于以同步放化疗为主的局部晚期头颈鳞癌,可考虑每周6次中度加速放疗以改善局部区域控制。
- 选择方案时需权衡局部控制获益与总生存无差异,并结合p16状态等因素个体化决策。
局限性
- 为基于区域指南差异的自然实验性队列研究,非随机对照设计,可能存在未测量混杂。
- 原文摘要未报告具体毒性数据及治疗中断情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiotherapy (RT) for patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) can be intensified by delivering 6 (6fx/w) instead of 5 (5fx/w) fractions per week. Randomized trials have demonstrated superiority for 6fx/w in patients treated without concurrent chemotherapy (CRT). This real-world analysis compares 6 vs 5 fx/w in LA-HNSCC all-comers, treated predominantly with CRT, where fractionation schedules were determined by region-specific guidelines, resembling a natural experiment. METHODS: All RT-treated patients from 2017 onwards across the six Swedish health care regions with T3-4 (all sites), T1-2 N3 (p16/HPV-positive oropharynx (HPV+ OPSCC)), T1-2N2c-N3 (all other sites) ≤ 70 years were included. Treatment schedules followed regional guidelines: three regions used 5fx/w, three used 6fx/w. Overall survival (OS) was the primary endpoint; loco-regional control (LRC) secondary. Multivariable Cox-Regressions and adjusted Kaplan-Meier estimates compared outcomes for patients treated at centers utilizing 5fx/w or 6fx/w. Data was acquired from the prospective Swedish Head and Neck Cancer Register. RESULTS: 405 (320 with CRT) treated at 6fx/w centers and 535 (352 with CRT) patients at 5fx/w centers were included. Median overall treatment time was 40 days (IQR 38-43) for 6fx/w and 46 days (IQR 46-49) for 5fx/w centers. Baseline characteristics were similar. Five-year OS was 67% for 6fx/w and 66% for 5fx/w (HR 0.93, 95%CI 0.73-1.19). Five-year LRC was significantly improved with 6fx/w (84%) vs 5fx/w (78%), HR 0.69 (95%CI 0.49-0.97). Findings remained in subgroup analyses, although the absolute benefit was larger for p16-negative HNSCC. CONCLUSION: Moderately accelerated RT with 6fx/w improved loco-regional control in LA-HNSCC patients treated mainly with CRT, without OS benefit.
引用
- Adrian G, Falklind NR, McDowell L, et al. Six versus five fractions per week (chemo)-radiotherapy for locally advanced head and neck squamous cell carcinoma - A nationwide cohort study from the Swedish head and neck cancer register. Radiother Oncol. 2026. PMID: 41802706. doi:10.1016/j.radonc.2026.111481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。